Free Trial
NYSE:MBX

MBX Biosciences (MBX) Stock Price, News & Analysis

MBX Biosciences logo
$9.17 -0.10 (-1.08%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$9.15 -0.02 (-0.16%)
As of 04/25/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MBX Biosciences Stock (NYSE:MBX)

Key Stats

Today's Range
$8.75
$9.64
50-Day Range
$5.79
$11.83
52-Week Range
$4.81
$27.50
Volume
265,788 shs
Average Volume
250,397 shs
Market Capitalization
$306.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50
Consensus Rating
Buy

Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

MBX Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

MBX MarketRank™: 

MBX Biosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 706th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MBX Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about MBX Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for MBX Biosciences are expected to grow in the coming year, from ($13.25) to ($2.30) per share.

  • Short Interest

    There is no current short interest data available for MBX.
  • Dividend Yield

    MBX Biosciences does not currently pay a dividend.

  • Dividend Growth

    MBX Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MBX.
  • News Sentiment

    MBX Biosciences has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for MBX Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for MBX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MBX Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,600,619.00 in company stock and sold $0.00 in company stock.

  • Read more about MBX Biosciences' insider trading history.
Receive MBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter.

MBX Stock News Headlines

2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
Ascendis Pharma initiated with an Outperform at RBC Capital
MBX Biosciences initiated with an Outperform at Citizens JMP
MBX Biosciences adds biotech veteran to board
See More Headlines

MBX Stock Analysis - Frequently Asked Questions

MBX Biosciences' stock was trading at $18.43 at the beginning of the year. Since then, MBX stock has decreased by 50.2% and is now trading at $9.17.
View the best growth stocks for 2025 here
.

MBX Biosciences, Inc. (NYSE:MBX) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($2.78) EPS for the quarter, missing the consensus estimate of ($2.72) by $0.06.

MBX Biosciences (MBX) raised $163 million in an initial public offering on Friday, September 13th 2024. The company issued 10,200,000 shares at a price of $16.00 per share.

MBX Biosciences' lock-up period expired on Wednesday, March 12th. MBX Biosciences had issued 10,200,000 shares in its IPO on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. Since the expiration of MBX Biosciences' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
11/07/2024
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:MBX
Previous Symbol
NYSE:MBX
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.50
High Stock Price Target
$44.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+308.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$306.50 million
Optionable
N/A
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NYSE:MBX) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners